Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Adrenocortical cancer (ACC) is a rare and aggressive cancer with dismal 5-year survival due to a lack of effective treatments. We aimed to identify a new effective combination of drugs and investigated their synergistic efficacy in ACC preclinical models.
A quantitative high-throughput drug screening of 4,991 compounds was performed on two ACC c...
Alternative Titles
Full title
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dedbd92387774c66a2f1443d619c0eaa
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dedbd92387774c66a2f1443d619c0eaa
Other Identifiers
ISSN
1756-9966,0392-9078
E-ISSN
1756-9966
DOI
10.1186/s13046-022-02464-5
